Amyloid PET imaging in clinical practice
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ..
Amyloid positron emission tomography (PET) imaging enables in vivo detection of brain Aβ deposition, one of the neuropathological hallmarks of Alzheimer's disease. There is increasing evidence to support its clinical utility, with major studies showing that amyloid PET imaging improves diagnostic accuracy, increases diagnostic certainty and results in therapeutic changes. The Amyloid Imaging Taskforce has developed appropriate use criteria to guide clinicians by predefining certain scenarios where amyloid PET would be justified. This review provides a practical guide on how and when to use amyloid PET, based on the available research and our own experience. We discuss its three main appropriate indications and illustrate these with clinical cases. We stress the importance of a multidisciplinary approach when deciding who might benefit from amyloid PET imaging. Finally, we highlight some practical points and common pitfalls in its interpretation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Practical neurology - 20(2020), 6 vom: 25. Dez., Seite 451-462 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kolanko, Magdalena A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
ALZHEIMER’S DISEASE |
|---|
| Anmerkungen: |
Date Completed 22.11.2021 Date Revised 15.03.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1136/practneurol-2019-002468 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM315438290 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM315438290 | ||
| 003 | DE-627 | ||
| 005 | 20231225154921.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/practneurol-2019-002468 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1051.xml |
| 035 | |a (DE-627)NLM315438290 | ||
| 035 | |a (NLM)32973035 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kolanko, Magdalena A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Amyloid PET imaging in clinical practice |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.11.2021 | ||
| 500 | |a Date Revised 15.03.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a Amyloid positron emission tomography (PET) imaging enables in vivo detection of brain Aβ deposition, one of the neuropathological hallmarks of Alzheimer's disease. There is increasing evidence to support its clinical utility, with major studies showing that amyloid PET imaging improves diagnostic accuracy, increases diagnostic certainty and results in therapeutic changes. The Amyloid Imaging Taskforce has developed appropriate use criteria to guide clinicians by predefining certain scenarios where amyloid PET would be justified. This review provides a practical guide on how and when to use amyloid PET, based on the available research and our own experience. We discuss its three main appropriate indications and illustrate these with clinical cases. We stress the importance of a multidisciplinary approach when deciding who might benefit from amyloid PET imaging. Finally, we highlight some practical points and common pitfalls in its interpretation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a ALZHEIMER’S DISEASE | |
| 650 | 4 | |a AMYLOID | |
| 650 | 4 | |a ATTENTION | |
| 650 | 4 | |a BEHAVIOURAL DISORDER | |
| 650 | 4 | |a COGNITION | |
| 650 | 4 | |a COGNITIVE NEUROPSYCHOLOGY | |
| 650 | 4 | |a VISUAL ATTENTION | |
| 650 | 7 | |a Amyloid |2 NLM | |
| 700 | 1 | |a Win, Zarni |e verfasserin |4 aut | |
| 700 | 1 | |a Loreto, Flavia |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Neva |e verfasserin |4 aut | |
| 700 | 1 | |a Carswell, Christopher |e verfasserin |4 aut | |
| 700 | 1 | |a Gontsarova, Anastassia |e verfasserin |4 aut | |
| 700 | 1 | |a Perry, Richard J |e verfasserin |4 aut | |
| 700 | 1 | |a Malhotra, Paresh A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Practical neurology |d 2007 |g 20(2020), 6 vom: 25. Dez., Seite 451-462 |w (DE-627)NLM169632148 |x 1474-7766 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2020 |g number:6 |g day:25 |g month:12 |g pages:451-462 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/practneurol-2019-002468 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2020 |e 6 |b 25 |c 12 |h 451-462 | ||